| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CDK7 |
| Uniprot No | P50613 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-346aa |
| 氨基酸序列 | MALDVKSRAKRYEKLDFLGEGQFATVYKARDKNTNQIVAIKKIKLGHRSEAKDGINRTALREIKLLQELSHPNIIGLLDAFGHKSNISLVFDFMETDLEVIIKDNSLVLTPSHIKAYMLMTLQGLEYLHQHWILHRDLKPNNLLLDENGVLKLADFGLAKSFGSPNRAYTHQVVTRWYRAPELLFGARMYGVGVDMWAVGCILAELLLRVPFLPGDSDLDQLTRIFETLGTPTEEQWPDMCSLPDYVTFKSFPGIPLHHIFSAAGDDLLDLIQGLFLFNPCARITATQALKMKYFSNRPGPTPGCQLPRPNCPVETLKEQSNPALAIKRKRTEALEQGGLPKKLIF |
| 预测分子量 | 41.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CDK7重组蛋白的模拟参考文献列表(内容为虚构，仅供参考)：
---
1. **文献名称**: *Structural insights into human CDK7 activation and its interaction with cyclin H*
**作者**: Smith, J. et al.
**摘要**: 本研究通过重组表达人源CDK7蛋白，结合X射线晶体学解析了CDK7与Cyclin H/MAT1复合物的三维结构，揭示了其激酶活性调控的分子机制，为靶向CDK7的抗癌药物设计提供了结构基础。
2. **文献名称**: *CDK7-dependent phosphorylation of RNA polymerase II drives transcription elongation*
**作者**: Johnson, R. et al.
**摘要**: 利用重组CDK7蛋白进行体外激酶实验，证明CDK7通过磷酸化RNA聚合酶II的C端结构域(CTD)调控转录延伸过程，并揭示了其在基因表达中的核心作用。
3. **文献名称**: *Targeting CDK7 with covalent inhibitors in triple-negative breast cancer*
**作者**: Brown, A. et al.
**摘要**: 研究基于重组CDK7蛋白筛选小分子抑制剂，发现一类共价抑制剂可选择性抑制CDK7激酶活性，并在三阴性乳腺癌模型中显著抑制肿瘤生长。
4. **文献名称**: *Reconstitution of the CDK7-cyclin H-MAT1 complex reveals its role in cell cycle progression*
**作者**: Lee, S. et al.
**摘要**: 通过重组CDK7、Cyclin H和MAT1蛋白重构功能性CAK复合体，证实其在CDK1/2激活及细胞周期G1/S转换中的必要性，并分析了复合体组装对激酶活性的影响。
---
注：以上文献信息为模拟生成，实际引用请查阅真实数据库(如PubMed、Web of Science)。
CDK7 (Cyclin-Dependent Kinase 7) is a serine/threonine kinase belonging to the CDK family, playing dual roles in cell cycle regulation and transcriptional control. It functions as a catalytic subunit of the CDK-activating kinase (CAK) complex, which phosphorylates and activates CDKs (e.g., CDK1. CDK2. CDK4/6) critical for cell cycle progression. Additionally, CDK7 is a component of the general transcription factor TFIIH, where it phosphorylates the C-terminal domain (CTD) of RNA polymerase II to initiate transcription. This dual functionality links CDK7 to fundamental cellular processes, making it a key target for studying cancer, neurodegenerative diseases, and transcriptional dysregulation.
Recombinant CDK7 proteins are engineered in vitro using expression systems like bacteria, yeast, or mammalian cells to ensure high purity and activity. These proteins retain the kinase domain’s structural integrity, enabling researchers to study enzymatic mechanisms, substrate interactions, and regulatory pathways in controlled settings. Recombinant CDK7 is widely used in biochemical assays, inhibitor screening, and structural studies (e.g., X-ray crystallography) to explore its role in diseases. For instance, CDK7 overexpression in cancers correlates with uncontrolled proliferation, driving interest in CDK7 inhibitors as potential therapeutics. Its involvement in transcription also highlights relevance in diseases tied to transcriptional stress.
The development of recombinant CDK7 has accelerated drug discovery, particularly for selective kinase inhibitors, while providing tools to dissect its non-canonical roles in metabolism and DNA repair. However, challenges remain in understanding isoform-specific functions and minimizing off-target effects in therapeutic contexts. Overall, recombinant CDK7 serves as a vital resource for both basic research and translational applications.
×
